Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2012

Open Access 01-12-2012 | Review

Novel regulatory therapies for prevention of Graft-versus-host disease

Authors: Joseph Leventhal, Yiming Huang, Hong Xu, Idona Goode, Suzanne T Ildstad

Published in: BMC Medicine | Issue 1/2012

Login to get access

Abstract

Graft-versus-host disease is one of the major transplant-related complications in allogeneic hematopoietic stem cell transplantation. Continued efforts have been made to prevent the occurrence of severe graft-versus-host disease by eliminating or suppressing donor-derived effector T cells. Conventional immunosuppression does not adequately prevent graft-versus-host disease, especially in mismatched transplants. Unfortunately, elimination of donor-derived T cells impairs stem cell engraftment, and delays immunologic reconstitution, rendering the recipient susceptible to post-transplant infections and disease relapse, with potentially lethal consequences. In this review, we discuss the role of dynamic immune regulation in controlling graft-versus-host disease, and how cell-based therapies are being developed using regulatory T cells and other tolerogenic cells for the prevention and treatment of graft-versus-host disease. In addition, advances in the design of cytoreductive conditioning regimens to selectively target graft-versus-host disease-inducing donor-derived T cells that have improved the safety of allogeneic stem cell transplantation are reviewed. Finally, we discuss advances in our understanding of the tolerogenic facilitating cell population, a phenotypically and functionally distinct population of bone marrow-derived cells which promote hematopoietic stem cell engraftment while reducing the risk of graft-versus-host disease.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Sakaguchi S: Regulatory T cells: history and perspective. Methods Mol Biol. 2011, 707: 3-17. 10.1007/978-1-61737-979-6_1.CrossRefPubMed
4.
Thornton AM, Shevach EM: CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998, 188: 287-296. 10.1084/jem.188.2.287.CrossRefPubMedPubMedCentral
5.
Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K: CD4(+)CD25(+) T cells facilitate the induction of T cell anergy. J Immunol. 2001, 167: 4271-4275.CrossRefPubMed
6.
Levings MK, Sangregorio R, Roncarolo MG: Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001, 193: 1295-1302. 10.1084/jem.193.11.1295.CrossRefPubMedPubMedCentral
7.
Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001, 193: 1285-1294. 10.1084/jem.193.11.1285.CrossRefPubMedPubMedCentral
8.
Ukena SN, Velaga S, Geffers R, Grosse J, Baron U, Buchholz S, Stadler M, Bruder D, Ganser A, Franzke A: Human regulatory T cells in allogeneic stem cell transplantation. Blood. 2011, 118: e82-92. 10.1182/blood-2011-05-352708.CrossRefPubMed
9.
Miyara M, Sakaguchi S: Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol Cell Biol. 2011, 89: 346-351. 10.1038/icb.2010.137.CrossRefPubMed
10.
Roncarolo MG, Battaglia M: Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol. 2007, 7: 585-598. 10.1038/nri2138.CrossRefPubMed
11.
Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA, McKinnon KP, Su L, Blazar BR, Serody JS: Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood. 2005, 106: 3300-3307. 10.1182/blood-2005-04-1632.CrossRefPubMedPubMedCentral
12.
Hasegawa H, Inoue A, Kohno M, Lei J, Miyazaki T, Yoshie O, Nose M, Yasukawa M: Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model. Gene Ther. 2008, 15: 171-182. 10.1038/sj.gt.3303051.CrossRefPubMed
13.
Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS: CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003, 9: 1144-1150. 10.1038/nm915.CrossRefPubMed
14.
Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S: Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002, 196: 389-399. 10.1084/jem.20020399.CrossRefPubMedPubMedCentral
15.
Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL: CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002, 196: 401-406. 10.1084/jem.20020090.CrossRefPubMedPubMedCentral
16.
Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del PB, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF: Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011, 117: 3921-3928. 10.1182/blood-2010-10-311894.CrossRefPubMed
17.
McMurchy AN, Bushell A, Levings MK, Wood KJ: Moving to tolerance: clinical application of T regulatory cells. Semin Immunol. 2011, 23: 304-313. 10.1016/j.smim.2011.04.001.CrossRefPubMed
18.
Trenado A, Charlotte F, Fisson S, Yagello M, Klatzmann D, Salomon BL, Cohen JL: Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003, 112: 1688-1696.CrossRefPubMedPubMedCentral
19.
Gaidot A, Landau DA, Martin GH, Bonduelle O, Grinberg-Bleyer Y, Matheoud D, Gregoire S, Baillou C, Combadiere B, Piaggio E, Cohen JL: Immune reconstitution is preserved in hematopoietic stem cell transplantation coadministered with regulatory T cells for GVHD prevention. Blood. 2011, 117: 2975-2983. 10.1182/blood-2010-08-299974.CrossRefPubMed
20.
Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, June CH, Miller JS, Wagner JE, Blazar BR: Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. 2011, 11: 1148-1157. 10.1111/j.1600-6143.2011.03558.x.CrossRefPubMedPubMedCentral
21.
Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE: Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011, 117: 1061-1070. 10.1182/blood-2010-07-293795.CrossRefPubMedPubMedCentral
22.
Magenau JM, Qin X, Tawara I, Rogers CE, Kitko C, Schlough M, Bickley D, Braun TM, Jang PS, Lowler KP, Jones DM, Choi SW, Reddy P, Mineishi S, Levine JE, Ferrara JL, Paczesny S: Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. Biol Blood Marrow Transplant. 2010, 16: 907-914. 10.1016/j.bbmt.2010.02.026.CrossRefPubMedPubMedCentral
23.
Fondi C, Nozzoli C, Benemei S, Baroni G, Saccardi R, Guidi S, Nicoletti P, Bartolozzi B, Pimpinelli N, Santucci M, Bosi A, Massi D: Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant. 2009, 15: 938-947. 10.1016/j.bbmt.2009.04.009.CrossRefPubMed
24.
Zinocker S, Sviland L, Dressel R, Rolstad B: Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. J Leukoc Biol. 2011, 90: 177-187. 10.1189/jlb.0211067.CrossRefPubMedPubMedCentral
25.
Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD: Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004, 104: 2187-2193. 10.1182/blood-2004-03-1040.CrossRefPubMed
26.
Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J: Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005, 106: 2903-2911. 10.1182/blood-2005-03-1257.CrossRefPubMedPubMedCentral
27.
Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, Ishikawa Y, Kato S, Sao H, Sakamaki H, Kawa K, Hamajima N, Asano S, Kodera Y: The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002, 99: 4200-4206. 10.1182/blood.V99.11.4200.CrossRefPubMed
28.
Hahn T, McCarthy PL, Zhang MJ, Wang D, Arora M, Frangoul H, Gale RP, Hale GA, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O: Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol. 2008, 26: 5728-5734. 10.1200/JCO.2008.17.6545.CrossRefPubMedPubMedCentral
29.
Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E, Kalaycio M: A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004, 34: 621-625. 10.1038/sj.bmt.1704647.CrossRefPubMed
30.
Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH: Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007, 109: 3108-3114.PubMedPubMedCentral
31.
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998, 92: 2303-2314.PubMed
32.
Colson YL, Wren SM, Schuchert MJ, Patrene KD, Johnson PC, Boggs SS, Ildstad ST: A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol. 1995, 155: 4179-4188.PubMed
33.
Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ: Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001, 98: 3456-3464. 10.1182/blood.V98.12.3456.CrossRefPubMed
34.
Luznik L, Engstrom LW, Iannone R, Fuchs EJ: Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant. 2002, 8: 131-138. 10.1053/bbmt.2002.v8.pm11939602.CrossRefPubMed
35.
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ: High-dose cyclophosphamide as single agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010, 115: 3224-3230. 10.1182/blood-2009-11-251595.CrossRefPubMedPubMedCentral
36.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolanos-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008, 14: 641-650. 10.1016/j.bbmt.2008.03.005.CrossRefPubMedPubMedCentral
37.
Li H, Colson YL, Ildstad ST: Mixed allogeneic chimerism achieved by lethal and nonlethal conditioning approaches induces donor-specific tolerance to simultaneous islet allografts. Transplantation. 1995, 60: 523-529. 10.1097/00007890-199509270-00001.CrossRefPubMed
38.
Mayumi H, Himeno K, Tanaka K, Tokuda N, Fan JL, Nomoto K: Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients. Transplantation. 1986, 42: 417-422. 10.1097/00007890-198610000-00018.CrossRefPubMed
39.
Luznik L, Fuchs EJ: High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010, 47: 65-77. 10.1007/s12026-009-8139-0.CrossRefPubMedPubMedCentral
40.
Luznik L, Jones RJ, Fuchs EJ: High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010, 17: 493-499. 10.1097/MOH.0b013e32833eaf1b.CrossRefPubMedPubMedCentral
41.
Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K: Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol. 1992, 149: 2668-2674.PubMed
42.
Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, Maris MB, Storb R: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003, 102: 756-762. 10.1182/blood-2002-08-2628.CrossRefPubMed
43.
Leventhal J, Abecassis M, Miller J, Gallon L, Ravindra K, Tollerud D, King B, Elliott MJ, Herzig G, Herzig R, Ildstad ST: Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med. 2012, 4: 1-10.CrossRef
44.
Kaufman CL, Colson YL, Wren SM, Watkins SL, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994, 84: 2436-2446.PubMed
45.
Gandy KL, Domen J, Aguila HL, Weissman IL: CD8+TCR+ and CD8+TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999, 11: 579-590. 10.1016/S1074-7613(00)80133-8.CrossRefPubMed
46.
Fugier-Vivier I, Rezzoug F, Huang Y, Graul-Layman AJ, Schanie CL, Xu H, Chilton PM, Ildstad ST: Plasmacytoid precursor dendritic cells facilitate allogeneic hematopoietic stem cell engraftment. J Exp Med. 2005, 201: 373-383. 10.1084/jem.20041399.CrossRefPubMedPubMedCentral
47.
Taylor KN, Shinde P, Colson YL: Reconstitution of allogeneic hemopoietic stem cells: the essential role of FcR{gamma} and the TCR beta-chain-FCp33 complex. J Immunol. 2006, 177: 1444-1450.CrossRefPubMed
48.
Colson YL, Christopher K, Glickman J, Taylor KN, Wright R, Perkins DL: Absence of clinical GVHD and the in vivo induction of regulatory T cells following facilitating cell transplantation. Blood. 2004, 104: 3829-3835. 10.1182/blood-2004-01-0393.CrossRefPubMed
49.
Taylor KN, Shinde-Patil VR, Cohick E, Colson YL: Induction of FoxP3+CD4+25+ regulatory T cells following hemopoietic stem cell transplantation: role of bone marrow-derived facilitating cells. J Immunol. 2007, 179: 2153-2162.CrossRefPubMed
50.
Huang Y, Bozulic LD, Miller T, Xu H, Hussain LR, Ildstad ST: CD8α+ plasmacytoid precursor DC induce antigen-specific regulatory T cells that enhance HSC engraftment in vivo. Blood. 2011, 117: 2494-2505. 10.1182/blood-2010-06-291187.CrossRefPubMedPubMedCentral
51.
Leventhal J, Gallon L, Miller J, Mehta J, Zakarija A, Abecassis M, Tollerud D, Herzig R, Ravindra K, Ildstad ST: Induction of donor specific tolerance in recipients of HLA disparate living donor kidney allografts by donor stem cell infusion [abstract]. Am J Transplant. 2011, 11: 76-[Meeting abstract 150]
Metadata
Title
Novel regulatory therapies for prevention of Graft-versus-host disease
Authors
Joseph Leventhal
Yiming Huang
Hong Xu
Idona Goode
Suzanne T Ildstad
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2012
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-10-48

Other articles of this Issue 1/2012

BMC Medicine 1/2012 Go to the issue

Minireview

New insights into the health effects of dietary saturated and omega-6 and omega-3 polyunsaturated fatty acids

Commentary

Ultramarathon is an outstanding model for the study of adaptive responses to extreme load and stress

Research article

Cardiac-specific catalase overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: role of oxidative stress and autophagy

Research article

CD133+CXCR4+ colon cancer cells exhibit metastatic potential and predict poor prognosis of patients

Opinion

Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals

Review

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus